fingolimod hydrochloride has been researched along with Lung Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Castagné, V; Debasly, S; Froget, G; Genest, L; Rupp, T | 1 |
| Chen, M; Chen, T; Hu, T; Li, Y; Ren, H; Yang, T | 1 |
| Booth, L; Dent, P; Poklepovic, A; Roberts, JL; Spiegel, S | 1 |
| Hino, H; Hiramoto, M; Kazama, H; Lorenzo, A; Miyazawa, K; Moriya, S; Okuma, T; Ota, K; Takano, N; Yokota, A | 1 |
| Arruda, DC; Bueno, V; Figueiredo, CR; Massaoka, MH; Matsuo, AL; Pereira, FV; Rodrigues, EG | 1 |
| Gu, Y; He, Z; Liu, H; Lu, M; Wang, C; Wang, H; Yin, J; Zhang, Z; Zheng, G | 1 |
| Carbone, M; Furuya, H; Gaudino, G; Giorgi, C; Larson, D; Li, S; Napolitano, A; Pass, HI; Pastorino, S; Pellegrini, L; Pinton, P; Szymiczek, A; Takinishi, Y; Tanji, M; Xue, J; Yang, H | 1 |
| Bueno, V; Cordeiro, JA; Cury, PM; Oshima, CT; Salinas, NR | 1 |
| Bueno, V; Lopes, CT; Oshima, CT; Palma, PV; Salinas, NR | 1 |
| Ruediger, R; Walter, G | 1 |
| Bielawski, J; De Palma, RM; Fedarovich, D; Garrett-Mayer, E; Gencer, S; Habib, AA; Liu, A; Mukhopadhyay, A; Oaks, J; Ogretmen, B; Perrotti, D; Peterson, YK; Saddoughi, SA; Selvam, SP; Senkal, CE; Stahelin, RV; Szulc, ZM; Thomas, RJ; Ward, KE | 1 |
| Bueno, V; Cordeiro, JA; Cury, PM; Lucas da Silva, LB; Ribeiro, DA | 1 |
12 other study(ies) available for fingolimod hydrochloride and Lung Neoplasms
| Article | Year |
|---|---|
Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lung Neoplasms; Mice; Tumor Microenvironment | 2022 |
Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Microtubule-Associated Proteins; Xenograft Model Antitumor Assays | 2018 |
Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 5; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Fingolimod Hydrochloride; Gene Knockdown Techniques; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; RNA, Small Interfering | 2019 |
Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
Topics: A549 Cells; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2019 |
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Propylene Glycols; Reactive Oxygen Species; Sphingosine; Time Factors | 2013 |
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Topics: Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Disease Progression; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Histone Chaperones; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Matrix Metalloproteinase 9; Mice; Neoplasm Staging; Prognosis; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Transplantation, Heterologous | 2015 |
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Fingolimod Hydrochloride; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Phosphatase 2; Tumor Suppressor Proteins | 2017 |
FTY720 and lung tumor development.
Topics: Adenoma; Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Proliferating Cell Nuclear Antigen; Propylene Glycols; Sphingosine; Urethane; Vascular Endothelial Growth Factor A | 2009 |
Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.
Topics: Adenoma; Animals; Apoptosis; Caspase 3; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Lung; Lung Neoplasms; Lysophospholipids; Male; Mice; Mice, Inbred BALB C; Proliferating Cell Nuclear Antigen; Propylene Glycols; Sphingosine; Urethane | 2009 |
Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
Topics: Animals; Benzopyrenes; Disease Models, Animal; Fingolimod Hydrochloride; Gene Knock-In Techniques; Humans; Immunosuppressive Agents; Lung Neoplasms; Mice; Mice, Knockout; Point Mutation; Propylene Glycols; Protein Phosphatase 2; ras Proteins; Signal Transduction; Sphingosine; Tumor Suppressor Protein p53 | 2012 |
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA-Binding Proteins; Fingolimod Hydrochloride; Gene Knockdown Techniques; Histone Chaperones; Humans; Lung Neoplasms; Mice; Mice, SCID; Models, Molecular; Necrosis; Phosphorylation; Propylene Glycols; Protein Phosphatase 2; Receptor-Interacting Protein Serine-Threonine Kinases; Sphingosine; Transcription Factors; Xenograft Model Antitumor Assays | 2013 |
FTY720 treatment in experimentally urethane-induced lung tumors.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Anticarcinogenic Agents; Carcinogens; Disease Models, Animal; Fingolimod Hydrochloride; Leukocytes, Mononuclear; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Propylene Glycols; Sphingosine; Spleen; Urethane | 2008 |